Related Experiment Video
Updated: Jun 26, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Overview of Novel Biomarkers for Management of Postchemotherapy Residual Masses in Testicular Cancer
Renjie Ding1, Xiangdong Li1, Zhuowei Liu1
1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Diagnosing residual masses after testicular cancer chemotherapy requires combining clinical, imaging, and blood tests. New biomarkers need more research to confirm their usefulness.
Area of Science:
- Oncology
- Medical Diagnostics
Background:
- Testicular cancer treatment often involves chemotherapy, which can leave residual masses.
- Accurate assessment of these masses is crucial for patient management and prognosis.
Purpose of the Study:
- To outline the current diagnostic standards for postchemotherapy residual masses in testicular cancer.
- To highlight the need for further investigation into novel biomarkers.
Main Methods:
- Review of existing diagnostic protocols for testicular cancer residual masses.
- Discussion of the roles of clinical evaluation, imaging techniques, and serological markers.
Main Results:
- Diagnosis relies on integrating clinical data, imaging results (e.g., CT scans, MRI), and serological tumor markers (e.g., AFP, hCG, LDH).
- Current methods provide a framework for assessing residual disease but have limitations.
Conclusions:
- A multimodal diagnostic approach is essential for accurately evaluating postchemotherapy residual masses in testicular cancer.
- Novel biomarkers show potential but require rigorous validation before clinical implementation.
